8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 21, 2007

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware	001-33380	87-0792558
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1901 Campus Place

Louisville, Kentucky 40299

(Address of principal executive offices)  (Zip Code)

(502) 263-7216

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.02	Termination of a Material Definitive Agreement and
Item 5.02	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 21, 2007, PharMerica Corporation (the “Company”) issued a press release stating that Mark McCullough, Executive Vice President and Chief Operating Officer of the Company, resigned to pursue other opportunities.

In connection with Mr. McCullough's resignation, Mr. McCullough and the Company entered into a Separation of Employment Agreement and General Release on September 21, 2007 to terminate Mr. McCullough's current employment agreement with the Company and set forth the terms of his separation with the Company.  Under the agreement, Mr. McCullough will be entitled to receive $450,000, to be paid in 15 equal monthly payments beginning on October 1, 2007.  Mr. McCullough will also be entitled to continuing health benefits for him and his family for an 18-month period following September 21, 2007.  Mr. McCullough will only receive benefits under the Company's incentive plan in accordance with the terms of the incentive plan and the award agreements to which he is a party.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits
99.1	Press Release of PharMerica Corporation dated September 21, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	PHARMERICA CORPORATION
Date: September 21, 2007	By: /s/ Thomas A. Caneris
	Thomas A. Caneris
	Senior Vice President, General Counsel and Secretary

Exhibit Index

Exhibit No.	Description
99.1	Press Release of PharMerica Corporation dated September 21, 2007.

EX-99.1

Exhibit 99.1

Contact:

Michael J. Culotta

Executive Vice President and Chief Financial Officer

(502) 627-7475

PHARMERICA CORPORATION ANNOUNCES

RESIGNATION OF CHIEF OPERATING OFFICER

LOUISVILLE, Kentucky (September 21, 2007) – PharMerica Corporation (NYSE: PMC) announced that, effective today, the Company’s Executive Vice President and Chief Operating Officer, Mark A. McCullough, has resigned to pursue other opportunities.

About PharMerica Corporation

PharMerica Corporation is an institutional pharmacy services provider dedicated to providing quality customer service and innovative pharmacy solutions to institutional customers and patients in long-term care settings.  PharMerica is a public company formed through the combination of the institutional pharmacy business of national healthcare services company Kindred Healthcare, Inc. and pharmaceutical services company AmerisourceBergen Corporation.  As a result of this combination, PharMerica ranks as an industry-leading U.S. provider of institutional pharmacy services in terms of annual revenues.  Headquartered in Louisville, Kentucky, PharMerica operates more than 120 institutional pharmacies in over 40 states that serve approximately 310,000 beds for patients of long-term facilities.  PharMerica has approximately 5,500 employees nationwide.  For more information, go to www.pharmerica.com.

-END-